Development PipelineDisitamab vedotin

a novel, investigational antibody–drug conjugate directed to HER2

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Clinical Trials

SGNDV-001: Urothelial cancer with HER2 expression

ClinicalTrials.Seagen.com ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

RC48 G001: Urothelial cancer with HER2 expression

ClinicalTrials.Seagen.com ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

SGNDV-005​: Locally advanced or metastatic solid tumors with HER2 expression

ClinicalTrials.Seagen.com ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

Program Resources

High-level synopsis of disitamab vedotin and ongoing clinical trials

View/Download

Detailed information about disitamab vedotin clinical trials

View in Interactive Pipeline

Related Links

List of Congress
Presentations

Related Medical Information
Documents

Medical Information
Request Form

Back to Pipeline